MIPrecise
Development and use of stable synthetic antibodies and designed receptors as diagnostic tools to reduce cancer treatment disparities
About the MIPrecise project
We are an EU funded MSCA Doctoral Network that will train thirteen doctoral candidates in developing synthetic antibodies (sAb) for guiding personalised therapies, for home based sampling and for biomarker discovery.
The project addresses inequalities in cancer health care by enabling at-home sampling and/or enrichment of scarce biomarkers and whole cells based on novel sAb and probes.
We will thereby aim to make progress related to the following cancer relevant topics:
- Assays for guiding personalized therapies based on kinase inhibitors
- Robust assays and home-based sampling for small cell lung cancer
- Discovery of new biomarkers for more precise cancer diagnostics
- Fast and sensitive liquid biopsies for assessment of tumour aggressiveness
The network is made up of twelve partners from six European countries providing international, intersectoral and interdisciplinary training that brings together chemists, material scientists, biologists and clinicians, to give each of our doctoral candidates doctoral training experience in the fields of molecular imprinting, smart materials, proteomics, single cell analysis, nanomedicine and clinical diagnostics.
MIPrecise is a four-year project funded by the EC HORIZON–MSCA-2024-DN Grant Agreement No 101226400, coordinated by Malmö University. The project starts 1st November 2025 and will end in October 2029.
Our network partners
Our Associate Partners undertaking training/secondments:
Latest news
Successful project kick-off meeting in Malmö
The MIPrecise consortium kick off meeting took place in Malmö, Sweden on Monday 15th December 2025 at the Biofilm Research Centre. The meeting included an open breakfast session introducing the project and the partners to other scientists within the Research...
MIPrecise opens recruitment
Cancer treatment outcomes vary widely due to inequalities in access to tests, drugs and the need for regular visits to specialist clinics. Many limitations can be addressed by developing more sensitive and robust tests for underexploited cancer biomarkers that can...